Remyelinating and neuroprotective treatments in multiple sclerosis

被引:11
|
作者
Stangel, M [1 ]
机构
[1] Hannover Med Sch, Dept Neurol, D-30625 Hannover, Germany
关键词
cannabinoids; cytokines; growth factors; intravenous immunoglobulins; multiple sclerosis; neuroprotection; neurotrophins; regeneration; remyelination; transplantation;
D O I
10.1517/eoid.13.4.331.29585
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Multiple sclerosis (MS) is the most common cause of neurological disability in young adults. The pathological hallmark is multifocal demyelination and inflammation in the CNS. In addition, there is also a variable extent of axonal damage. Remyelination has been seen in up to 70% of lesions but repair is generally incomplete. The demonstration of neuropathological heterogeneity of MS lesions suggests different pathophysiological sub-types and it is therefore unlikely that there is a uniform cause of incomplete remyelination in MS. In recent years, a great body of knowledge has accumulated in order to better understand the regulatory mechanisms of remyelination. This has led to a number of approaches to promote repair mechanisms, most of which have been successful in animal experiments. Unfortunately, the translation of these experimental data into clinical treatments has proven difficult. More information on the pathogenesis of MS, the reason why repair mechanisms fail in MS and a better understanding of the regulation of remyelination are required. This will ultimately lead to a specific treatment tailored for the individual patient and will probably involve a combination of immunomodulation, remyelination and neuroprotection.
引用
收藏
页码:331 / 347
页数:17
相关论文
共 50 条
  • [21] The future of multiple sclerosis treatments
    Coclitu, Catalina
    Constantinescu, Cris S.
    Tanasescu, Radu
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2016, 16 (12) : 1341 - 1356
  • [22] Emerging treatments in multiple sclerosis
    Schluep, M
    Bogousslavsky, J
    EUROPEAN NEUROLOGY, 1997, 38 (03) : 216 - 221
  • [23] Multiple sclerosis : emerging treatments
    Lubetzki, Catherine
    BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2010, 194 (4-5): : 745 - 750
  • [24] New treatments for multiple sclerosis
    Hutchinson, M
    IRISH MEDICAL JOURNAL, 1996, 89 (02) : 44 - 44
  • [25] Update on multiple sclerosis treatments
    Bridel, Claire
    Lalive, Patrice H.
    SWISS MEDICAL WEEKLY, 2014, 144
  • [26] Current treatments for multiple sclerosis
    Kernich, CA
    NEUROLOGIST, 2005, 11 (02) : 137 - 138
  • [27] Novel treatments for multiple sclerosis
    Kwok, Billy
    Levine, Hester A.
    Marinkovicova, Lenka
    O'Toole, Eileen
    Rudolf, Anne K.
    Shanley, John
    Dev, Kumlesh K.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2013, 182 : S10 - S10
  • [28] New treatments for multiple sclerosis
    Kilpatrick, TJ
    Soilu-Hänninen, M
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 1999, 29 (06): : 801 - 810
  • [29] CN045 is a novel small molecule lead for remyelinating therapies in multiple sclerosis
    Yang, Y.
    Medicetty, S.
    Knutsen, L.
    Hamlyn, R.
    Trapp, B.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 351 - 351
  • [30] Placebo controlled pilot trial to study the remyelinating potential of intravenous immunoglobulins in multiple sclerosis
    Stangel, M
    Boegner, F
    Klatt, CH
    Hofmeister, C
    Seyfert, S
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2000, 68 (01): : 89 - 92